Convex has advised Redditch Medical, a UK-based specialist in cleanroom contamination control solutions, including the InSpec® range of disinfectants and detergents, on a strategic sale to Schülke & Mayr (“schülke”) the leading provider of sustainable infection prevention and treatment solutions for the healthcare and life sciences industry.
Headquartered in Norderstedt near Hamburg, Schülke & Mayr GmbH has been a global leader in infection prevention and control for over 135 years. schülke’s mission is to protect lives worldwide by providing critical hygiene solutions that effectively combat risks for humans and materials from infection and contamination. schülke is owned by a shareholder consortium led by the Munich-based single-family office ATHOS, with heritage in healthcare and life sciences.
This strategic acquisition expands schülke’s Life Science capabilities and reinforces their commitment to seamless cleanroom decontamination for pharmaceutical and biotech customers worldwide.
Founded in 2012, Redditch Medical is a UK-based specialist in cleanroom contamination control for the Life Sciences industry. The company develops and manufactures the InSpec® range of disinfectants and detergents, designed for broad-spectrum efficacy and compliant with EN standards and Biocidal Products Regulation (BPR). All products are produced in-house under ISO 5 cleanroom conditions and in accordance with ISO 9001 and GMP principles. Redditch Medical’s validation team provides expert technical support, microbiological and chemical analytics, and tailored solutions for pharmaceutical and biotech cleanroom environments.
Jan-Dirk Auris, CEO of schülke, commented: “Redditch Medical brings deep expertise in sterile cleanroom solutions that perfectly complements our Life Science portfolio. This acquisition is a decisive step forward in our mission to protect lives worldwide.”
The acquisition of Redditch Medical will strengthen the company’s ability to deliver tailored solutions to their customers in the pharmaceutical and biotech sectors. Redditch’s InSpec® product line and technical validation services will enhance the company’s offering in cleanroom contamination control. It will expand schülke’s footprint beyond current geographies, allowing it to serve more customers across Europe and globally.
Patric Scheidner, Head of SBU Life Science at schülke, added: “We are excited to welcome Redditch Medical to our Life Science team. Their product innovation and manufacturing excellence will enable us to accelerate our growth and better serve our customers’ evolving needs more effectively.”
Steve Brown, CEO of Redditch Medical, stated: “Joining schülke is a great opportunity for our team and our customers. We share a common vision of quality, safety, and innovation, and we look forward to contributing to schülke’s mission.”
This acquisition marks a new chapter in schülke’s Life Science strategy. With combined expertise and shared values, schülke and Redditch Medical will drive innovation in cleanroom contamination control and deliver measurable value to customers across the pharmaceutical and biotech sectors.
For more information about Redditch Medical visit their website.
